Johnson & Johnson’s experimental Covid-19 vaccine phase 1/2 trial findings have provided some encouragement.
- induced immune responses in most people who received the shot
- displayed an acceptable safety profile
Now for some caveats. These are from a small early-stage trial. They are interim, posted on online preprint server medRxiv. The report is not yet peer-reviewed, not yet published in medical journals.
J&J have said that they’ll now carry on with a larger late-stage study of up to 60,000 people that will provide more definitive evidence.
- The vaccine — called Ad26.COV2.S — uses the same technology used for Johnson & Johnson’s Ebola, Zika, HIV and RSV vaccines.